Blue Faery Welcomes Eisai to its Corporate Council

    LOS ANGELES, CA, October 01, 2019 /24-7PressRelease/ -- Blue Faery: The Adrienne Wilson Liver Cancer Association is thrilled to have Eisai as a founding member of its new corporate giving endeavor titled Blue Faery Benefactors Council. The national membership program consists of corporations and/or individuals committed to giving an annual gift for Hepatocellular Carcinoma (HCC) research, HCC educational programs, patient advocacy events and/or corporate sponsorships.

President Andrea Wilson said, "Eisai has been a pioneer in the fight against Hepatocellular Carcinoma. They have always been supportive of our efforts to educate and advocate for HCC patients and caregivers. We value their partnership in the fight against primary liver cancer."

Teresa Cronin, Director, Corporate Advocacy at Eisai Inc. stated, "We are honored to be a founding member of Blue Faery's Benefactors Council. As a company, we are driven by our human health care mission, through which we strive to connect with patients and their families in a meaningful way and are proud to align ourselves with organizations like Blue Faery who share this vision."

About Blue Faery
Founded in 2002, the mission of Blue Faery is to prevent, treat and cure primary liver cancer through research, education and advocacy. Blue Faery's HCC patient education brochure is free for patients, their families and their healthcare providers. To serve the needs of HCC patients worldwide, Blue Faery's website translates into 10 languages including Chinese, Hindi, Korean and Spanish. Blue Faery hosts an online Liver Cancer Community for patients and caregivers and gives an annual award to recognize researchers who have made significant contributions in the advancement of scientific knowledge in the diagnosis, treatment, prevention or understanding of primary liver cancer.

About Eisai
Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan, with approximately 10,000 employees worldwide. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. We strive to realize our hhc philosophy by delivering innovative products in therapeutic areas with high unmet medical needs, including Oncology and Neurology. In the spirit of hhc, we take that commitment even further by applying our scientific expertise, clinical capabilities and patient insights to discover and develop innovative solutions that help address society's toughest unmet needs, including neglected tropical diseases and the Sustainable Development Goals.

# # #